Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag

Cytokinetics Inc.

CYTK Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown
CYTK Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
CYTK Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CYTK Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in CYTK holdings by institutional investors

Quarterly net insider trading by CYTK's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $30,000 Jul 20, 2026 Issue: Health Issues
  • $30,000 Apr 20, 2026 Issue: Health Issues
  • $30,000 Jan 20, 2026 Issue: Health Issues
  • $30,000 Oct 20, 2025 Issue: Health Issues
  • $30,000 Jul 21, 2025 Issue: Health Issues
  • $30,000 Apr 21, 2025 Issue: Health Issues
  • $10,000 Jan 16, 2025 Issue: Health Issues

Former government officials who have lobbied for CYTK

7 former government officials from 5 congressional offices at 1 lobbying firm have lobbied for CYTK, most recently Jul 20, 2026.

  • John B. Breaux
    Sarah Walter Senate Former Legislative Director/Chief Counsel, Sen. John Breaux Formerly with John B. Breaux · FARRAGUT PARTNERS LLP · Jul 20, 2026
  • Edward Whitfield Congress U.S. Representatives (21 yrs.) Formerly U.S. Representatives (21 yrs.) · FARRAGUT PARTNERS LLP · Jul 20, 2026
  • Kristen Bautz House Senior Advisor and Special Projects Coordinator, Rep Wasserman Shultz Formerly Wasserman Shultz · FARRAGUT PARTNERS LLP · Jul 20, 2026
  • Ed Whitfield
    Jeffery Mortier House Prof Staff on E&C Cmte, LA Rep Whitfield and Intern Devin Nunes Formerly with Ed Whitfield · FARRAGUT PARTNERS LLP · Jul 20, 2026
  • Joe Barton
    Jeff Mackinnon House LD & LA Rep. Joe Barton (RTexas) Formerly with Joe Barton · FARRAGUT PARTNERS LLP · Jul 20, 2026
  • John A. Boehner
    Dylan Moore House Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8); Intern, Rep. Mike Turner (OH-10) Formerly with John A. Boehner · FARRAGUT PARTNERS LLP · Jul 20, 2026
  • Daniel Coats
    Constantine Hingson Senate New Chief of Staff, Senator Dan Coats; Counsel/Legislative Director, Senator Judd Gregg; General Counsel, Senator Elizabeth Dole Formerly with Daniel Coats · FARRAGUT PARTNERS LLP · Jul 20, 2026

CYTK Estimated quarterly lobbying spending

CYTK Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
CYTK Income Statement
CYTK Balance Sheet
CYTK Cash Flow
U.S. Patents

New CYTK patent grants

  • Patent Title: Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use Jun. 12, 2018
  • Patent Title: Amino-pyrimidine skeletal muscle modulators Aug. 15, 2017
  • Patent Title: Substituted pyridazines as skeletal muscle modulators Mar. 28, 2017
  • Patent Title: Certain heterocycles, compositions thereof, and methods for their use Mar. 08, 2016
  • Patent Title: Compounds, compositions and methods Oct. 06, 2015
  • Patent Title: Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use Sep. 15, 2015
  • Patent Title: Certain amino-pyrimidines, compositions thereof, and methods for their use Apr. 28, 2015
  • Patent Title: Amino-pyridazine skeletal muscle modulators Mar. 03, 2015
  • Patent Title: Certain amino-pyrimidines, compositions thereof, and methods for their use Feb. 24, 2015
  • Patent Title: Certain chemical entities, compositions, and methods Nov. 25, 2014
  • Patent Title: Ureas and their use in the treatment of heart failure Oct. 28, 2014
  • Patent Title: Certain chemical entities, compositions and methods Oct. 28, 2014
  • Patent Title: Imidazole-benzamide anti-cancer agents Jul. 08, 2014
  • Patent Title: Certain heterocycles, compositions thereof, and methods for their use Jun. 24, 2014
  • Patent Title: Certain chemical entities, compositions, and methods Jun. 24, 2014
  • Patent Title: Certain 1h-imidazo[4,5-b]pyrazin-2(3h)-ones and 1h-imidazo[4,5-b]pyrazin-2-ols and methods for their use May. 06, 2014
  • Patent Title: Certain heterocycles, compositions thereof, and methods for their use Apr. 01, 2014
  • Patent Title: Methods and compositions utilizing quinazolinones Feb. 25, 2014
  • Patent Title: Certain chemical entities, compositions, and methods Feb. 18, 2014
  • Patent Title: Compounds, compositions and methods Jan. 21, 2014
  • Patent Title: Heterocyclic sulfonamides Dec. 10, 2013
  • Patent Title: Ureas and their use in the treatment of heart failure Aug. 20, 2013
  • Patent Title: Methods and compositions utilizing quinazolinones Jun. 25, 2013
  • Patent Title: Certain chemical entities, compositions and methods May. 21, 2013
  • Patent Title: Certain chemical entities, compositions and methods Apr. 02, 2013
  • Patent Title: Heterocyclic sulfonamides Feb. 05, 2013
  • Patent Title: Compounds, compositions and methods Dec. 11, 2012
  • Patent Title: Certain 1h-imidazo[4,5-b]pyrazin-2(3h)-ones and 1h-imidazo[4,5-b]pyrazin-2-ols and methods for their use Oct. 30, 2012
  • Patent Title: Certain chemical entities, compositions and methods Oct. 23, 2012
  • Patent Title: Modulating skeletal muscle Jul. 24, 2012
  • Patent Title: Imidazopyridinyl benzamide mitotic kinesin inhibitors Jun. 26, 2012
  • Patent Title: Heterocyclic sulfonamides Jun. 19, 2012
  • Patent Title: Imidazopyridinyl benzamide mitotic kinesin inhibitors Apr. 24, 2012
  • Patent Title: Compounds, compositions and methods Feb. 21, 2012
  • Patent Title: Ureas and their use in the treatment of heart failure Feb. 07, 2012
  • Patent Title: Heterocyclic sulfonamides Jan. 24, 2012
  • Patent Title: Certain chemical entities, compositions, and methods Jan. 03, 2012
  • Patent Title: Certain chemical entities, compositions, and methods Dec. 06, 2011
  • Patent Title: Certain chemical entities, compositions, and methods Nov. 22, 2011
  • Patent Title: Methods and compostions utilizing quinazolinones Aug. 30, 2011
  • Patent Title: Certain chemical entities, compositions and methods Aug. 16, 2011
  • Patent Title: Certain chemical entities, compositions, and methods Aug. 02, 2011
  • Patent Title: Compounds, compositions and methods Aug. 02, 2011
  • Patent Title: Certain 1h-imidazo[4,5-b]pyrazin-2(3h)-ones and 1h-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use Jun. 07, 2011
  • Patent Title: Certain chemical entities, compositions, and methods May. 10, 2011
  • Patent Title: Certain chemical entities, compositions, and methods May. 10, 2011
  • Patent Title: Certain chemical entities, compositions, and methods Apr. 26, 2011
  • Patent Title: Compounds, compositions and methods Apr. 05, 2011
  • Patent Title: Certain chemical entities, compositions, and methods Apr. 05, 2011
  • Patent Title: Compounds, compositions and methods Mar. 22, 2011
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to CYTK from public contracts

CYTK News

Recent insights relating to CYTK

CNBC Recommendations

Recent picks made for CYTK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CYTK

CYTK Analyst Ratings

CYTK Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
CYTK Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $CYTK stock a Buy, Sell, or Hold?

  • What is the price target for $CYTK stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

CYTK Top Shareholders
Shareholder
Shares Held
CYTK Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $CYTK stock?

  • Who owns the most shares of $CYTK stock?

  • What funds own $CYTK stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CYTK Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CYTK Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About CYTK

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

  • Address South San Francisco, CA
  • Market Cap 9.1 billion
  • Employees 673
  • Industrial Classification Pharmaceutical Preparations

Cytokinetics Inc. (CYTK) Historical Stock Prices

Cytokinetics Inc. (CYTK) closed at $65.81 on September 23, 2026. Over the past year its adjusted close ranged from $47.83 to $87.26. Daily prices go back to January 2, 2014, 3,199 trading days in all.

  • 1 month-14.63%
  • 3 months-18.95%
  • Year to date+3.57%
  • 1 year+35.55%
  • 3 years+112.63%
  • 5 years+98.64%
  • Max+879.32%
See every congressional and insider trade on the CYTK price chart

Quiver Premium charts CYTK's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 67.02 67.39 64.72 65.81 65.81 2,050,950
Sep 22, 2026 68.07 69.56 67.48 67.59 67.59 2,388,591
Sep 21, 2026 69.30 69.50 67.35 67.56 67.56 1,603,484
Sep 18, 2026 70.18 70.18 68.15 68.78 68.78 4,872,972
Sep 17, 2026 70.64 71.05 68.92 69.92 69.92 1,398,170
Sep 16, 2026 69.52 70.68 68.67 69.39 69.39 2,211,795
Sep 15, 2026 72.13 72.19 68.55 69.31 69.31 2,576,731
Sep 14, 2026 73.50 74.65 72.34 72.45 72.45 1,533,560
Sep 11, 2026 74.66 75.98 73.50 73.77 73.77 1,721,518
Sep 10, 2026 73.23 75.10 73.13 73.62 73.62 1,444,873
Sep 9, 2026 74.31 74.89 73.52 74.11 74.11 1,424,847
Sep 8, 2026 72.39 76.81 72.39 75.35 75.35 1,921,008
Sep 4, 2026 73.04 74.01 72.25 72.72 72.72 1,140,923
Sep 3, 2026 73.55 74.22 71.41 73.95 73.95 1,589,734
Sep 2, 2026 71.90 73.70 70.42 71.93 71.93 1,605,679
Sep 1, 2026 69.85 72.45 69.83 71.40 71.40 1,899,653
Aug 31, 2026 71.54 71.79 69.31 70.91 70.91 3,078,140
Aug 28, 2026 73.88 74.42 71.66 72.09 72.09 4,361,525
Aug 27, 2026 78.84 79.13 77.84 77.90 77.90 1,109,945
Aug 26, 2026 77.91 79.88 76.70 79.20 79.20 1,236,620
Aug 25, 2026 77.93 78.72 77.21 77.46 77.46 1,260,832
Aug 24, 2026 77.20 77.99 75.65 77.09 77.09 1,212,285
Aug 21, 2026 77.30 77.70 76.65 76.84 76.84 1,521,261
Aug 20, 2026 77.36 77.62 76.14 77.18 77.18 1,651,714
Aug 19, 2026 77.23 77.88 76.17 77.74 77.74 1,505,964
Aug 18, 2026 75.57 76.81 74.76 76.10 76.10 1,653,100
Aug 17, 2026 73.90 75.92 73.46 75.87 75.87 1,492,023
Aug 14, 2026 72.70 74.26 72.12 74.13 74.13 1,756,968
Aug 13, 2026 76.80 76.81 73.40 73.45 73.45 1,771,363
Aug 12, 2026 76.71 77.71 75.34 75.64 75.64 2,105,583
Aug 11, 2026 78.65 78.95 76.30 76.45 76.45 1,270,141
Aug 10, 2026 76.09 77.89 75.67 77.49 77.49 2,270,664
Aug 7, 2026 81.23 81.50 75.87 76.76 76.76 3,604,464
Aug 6, 2026 78.94 81.77 78.75 81.37 81.37 2,523,490
Aug 5, 2026 79.42 80.49 77.70 78.85 78.85 1,594,167
Aug 4, 2026 77.25 79.82 76.70 78.61 78.61 2,447,492
Aug 3, 2026 76.69 77.17 74.89 76.45 76.45 2,240,096
Jul 31, 2026 80.32 80.81 76.96 77.13 77.13 1,579,231
Jul 30, 2026 78.39 80.84 77.90 80.42 80.42 2,092,473
Jul 29, 2026 79.77 80.34 78.07 78.39 78.39 1,780,885
Jul 28, 2026 81.02 81.02 78.98 79.45 79.45 1,659,987
Jul 27, 2026 81.51 82.41 79.90 80.62 80.62 1,835,104
Jul 24, 2026 82.59 82.59 80.28 80.74 80.74 1,638,260
Jul 23, 2026 80.89 82.99 80.06 81.92 81.92 1,076,211
Jul 22, 2026 81.28 83.83 80.61 82.19 82.19 2,072,345
Jul 21, 2026 78.97 81.55 78.81 81.11 81.11 1,215,829
Jul 20, 2026 80.44 81.31 78.87 79.11 79.11 1,468,722
Jul 17, 2026 78.99 82.58 78.27 80.18 80.18 1,588,488
Jul 16, 2026 82.49 83.71 79.81 80.36 80.36 1,406,793
Jul 15, 2026 81.03 82.76 80.33 82.62 82.62 1,334,079
Jul 14, 2026 83.00 83.44 80.61 81.93 81.93 1,439,629
Jul 13, 2026 83.39 84.60 80.90 82.24 82.24 1,891,495
Jul 10, 2026 86.16 86.45 83.59 84.87 84.87 1,768,032
Jul 9, 2026 84.48 86.20 83.61 86.07 86.07 1,691,646
Jul 8, 2026 85.00 85.87 82.20 84.88 84.88 2,377,531
Jul 7, 2026 86.08 87.93 85.55 85.56 85.56 2,293,475
Jul 6, 2026 86.04 86.88 84.45 85.57 85.57 2,239,559
Jul 2, 2026 86.09 87.42 84.62 86.49 86.49 2,030,297
Jul 1, 2026 85.02 85.48 83.90 85.26 85.26 2,147,458
Jun 30, 2026 87.79 88.31 84.89 85.19 85.19 2,403,866
Jun 29, 2026 85.00 87.35 84.51 87.26 87.26 3,635,432
Jun 26, 2026 80.80 84.55 80.04 82.19 82.19 7,164,201
Jun 25, 2026 80.84 82.95 80.37 80.80 80.80 2,386,645
Jun 24, 2026 80.53 82.83 79.12 81.20 81.20 2,425,736
Jun 23, 2026 78.99 80.40 78.27 80.01 80.01 2,077,619
Jun 22, 2026 80.00 80.80 78.36 79.17 79.17 2,888,382
Jun 18, 2026 79.41 80.15 77.14 78.78 78.78 3,547,472
Jun 17, 2026 75.80 79.30 75.75 78.11 78.11 3,340,445
Jun 16, 2026 73.00 77.00 72.15 75.21 75.21 3,973,985
Jun 15, 2026 70.15 71.38 68.84 71.38 71.38 1,012,618
Jun 12, 2026 69.74 71.25 69.06 70.15 70.15 1,292,937
Jun 11, 2026 67.50 70.55 67.45 69.27 69.27 1,443,394
Jun 10, 2026 68.06 70.29 66.63 67.07 67.07 1,404,875
Jun 9, 2026 68.60 70.33 66.85 68.45 68.45 2,492,667
Jun 8, 2026 72.00 72.83 67.78 67.90 67.90 2,382,475
Jun 5, 2026 72.84 73.47 70.58 71.48 71.48 1,614,067
Jun 4, 2026 71.07 72.75 70.72 72.29 72.29 1,312,433
Jun 3, 2026 70.65 72.00 70.17 70.71 70.71 1,595,143
Jun 2, 2026 72.47 73.63 70.30 70.91 70.91 1,488,012
Jun 1, 2026 76.09 76.48 73.18 73.68 73.68 1,659,897
May 29, 2026 76.67 77.11 75.66 76.76 76.76 1,844,618
May 28, 2026 77.28 78.85 75.00 76.81 76.81 1,972,009
May 27, 2026 76.41 77.91 75.86 77.15 77.15 1,622,201
May 26, 2026 77.01 77.26 75.50 76.29 76.29 1,652,111
May 22, 2026 78.39 78.92 76.58 76.94 76.94 1,111,298
May 21, 2026 78.39 79.09 77.60 78.06 78.06 1,775,261
May 20, 2026 77.08 79.12 76.30 78.77 78.77 2,379,527
May 19, 2026 75.65 76.78 73.00 76.45 76.45 2,399,087
May 18, 2026 75.81 76.55 74.64 75.18 75.18 1,798,155
May 15, 2026 78.40 78.51 75.48 75.85 75.85 1,829,793
May 14, 2026 77.09 78.84 75.80 78.64 78.64 2,349,146
May 13, 2026 74.76 77.35 74.31 77.22 77.22 2,214,747
May 12, 2026 74.68 75.23 73.13 74.81 74.81 2,418,515
May 11, 2026 77.66 78.49 74.16 74.56 74.56 5,316,878
May 8, 2026 74.51 78.80 74.51 76.91 76.91 5,791,776
May 7, 2026 74.50 76.25 72.75 74.29 74.29 8,401,463
May 6, 2026 78.38 79.01 72.15 74.84 74.84 4,803,404
May 5, 2026 74.69 80.20 73.06 77.09 77.09 18,079,520
May 4, 2026 63.00 67.05 63.00 66.05 66.05 2,156,293
May 1, 2026 63.97 65.29 62.92 63.35 63.35 2,459,508
Apr 30, 2026 59.69 64.30 59.69 63.97 63.97 2,723,469
Apr 29, 2026 60.01 60.59 58.65 59.58 59.58 2,352,872
Apr 28, 2026 62.44 63.60 60.60 60.69 60.69 2,213,140
Apr 27, 2026 65.41 65.87 61.15 61.60 61.60 2,261,409
Apr 24, 2026 65.50 65.77 63.79 65.32 65.32 967,139
Apr 23, 2026 65.97 67.26 64.60 65.48 65.48 1,662,178
Apr 22, 2026 66.43 66.51 64.99 66.25 66.25 1,181,441
Apr 21, 2026 66.01 66.36 64.53 65.80 65.80 1,174,830
Apr 20, 2026 66.70 66.90 65.87 66.14 66.14 1,027,493
Apr 17, 2026 66.35 67.04 65.14 66.71 66.71 1,499,226
Apr 16, 2026 65.60 65.63 63.97 65.42 65.42 1,168,813
Apr 15, 2026 66.65 67.25 64.74 65.37 65.37 1,259,908
Apr 14, 2026 66.77 67.52 65.94 66.35 66.35 1,897,144
Apr 13, 2026 65.01 67.90 64.58 66.72 66.72 1,728,625
Apr 10, 2026 64.71 65.57 63.95 65.01 65.01 1,224,434
Apr 9, 2026 65.67 65.67 64.21 64.59 64.59 1,364,665
Apr 8, 2026 67.50 67.77 65.58 65.77 65.77 1,755,975
Apr 7, 2026 64.75 66.16 64.25 65.48 65.48 1,327,626
Apr 6, 2026 66.09 66.66 64.67 64.94 64.94 1,314,251
Apr 2, 2026 66.15 68.71 65.42 66.73 66.73 2,479,314
Apr 1, 2026 66.55 67.92 65.95 66.61 66.61 2,366,541
Mar 31, 2026 63.80 67.11 63.80 65.91 65.91 1,731,642
Mar 30, 2026 62.80 63.67 61.67 62.97 62.97 2,443,222
Mar 27, 2026 63.44 64.74 62.22 62.50 62.50 1,701,852
Mar 26, 2026 61.95 64.62 61.89 63.48 63.48 2,201,651
Mar 25, 2026 60.12 62.39 60.11 62.39 62.39 2,102,617
Mar 24, 2026 60.54 60.54 59.03 60.02 60.02 2,106,336
Mar 23, 2026 63.00 63.47 60.78 60.95 60.95 1,523,247
Mar 20, 2026 62.61 63.98 61.02 61.70 61.70 3,212,529
Mar 19, 2026 62.00 63.80 61.53 62.95 62.95 1,849,420
Mar 18, 2026 61.50 63.03 60.82 62.19 62.19 1,983,853
Mar 17, 2026 60.94 63.11 60.51 62.13 62.13 3,271,222
Mar 16, 2026 61.03 61.91 59.19 60.83 60.83 2,098,864
Mar 13, 2026 60.49 61.79 58.43 60.06 60.06 1,933,991
Mar 12, 2026 62.79 62.88 59.45 60.00 60.00 2,219,305
Mar 11, 2026 63.73 63.83 61.46 63.63 63.63 1,758,203
Mar 10, 2026 62.24 64.68 60.87 64.20 64.20 2,114,562
Mar 9, 2026 60.35 62.72 59.91 62.42 62.42 2,558,088
Mar 6, 2026 61.38 61.38 59.63 60.41 60.41 1,802,708
Mar 5, 2026 61.39 62.46 60.82 62.19 62.19 1,535,720
Mar 4, 2026 60.92 62.57 60.01 62.27 62.27 2,369,585
Mar 3, 2026 60.29 61.50 59.33 60.72 60.72 2,174,722
Mar 2, 2026 61.62 62.53 60.45 61.43 61.43 1,459,789
Feb 27, 2026 62.08 62.99 61.91 62.22 62.22 1,432,239
Feb 26, 2026 62.61 63.00 60.87 62.63 62.63 1,997,293
Feb 25, 2026 68.12 69.28 62.00 62.89 62.89 5,040,785
Feb 24, 2026 68.44 70.39 67.02 70.10 70.10 1,946,703
Feb 23, 2026 67.85 68.92 67.52 68.26 68.26 1,492,647
Feb 20, 2026 67.72 69.12 67.45 67.94 67.94 2,024,687
Feb 19, 2026 66.61 67.86 65.54 67.83 67.83 1,261,958
Feb 18, 2026 66.31 67.67 66.01 66.98 66.98 1,581,440
Feb 17, 2026 65.98 66.99 65.51 66.62 66.62 1,126,688
Feb 13, 2026 65.49 67.54 64.58 66.26 66.26 2,080,101
Feb 12, 2026 67.00 67.89 64.64 65.04 65.04 1,732,504
Feb 11, 2026 65.25 66.98 63.53 66.80 66.80 1,952,899
Feb 10, 2026 63.96 65.49 63.13 64.85 64.85 2,433,044
Feb 9, 2026 62.21 63.67 61.58 63.36 63.36 1,069,855
Feb 6, 2026 61.31 62.74 61.00 62.34 62.34 1,736,718
Feb 5, 2026 63.26 64.51 60.05 60.24 60.24 2,071,827
Feb 4, 2026 64.97 65.25 62.35 63.52 63.52 1,604,189
Feb 3, 2026 65.86 67.09 63.64 64.73 64.73 1,434,906
Feb 2, 2026 62.10 65.63 62.05 65.16 65.16 1,346,736
Jan 30, 2026 65.00 65.74 62.79 63.19 63.19 1,932,972
Jan 29, 2026 65.22 65.88 64.28 65.60 65.60 1,882,600
Jan 28, 2026 64.61 65.31 63.99 65.14 65.14 1,244,664
Jan 27, 2026 63.29 65.98 63.15 64.01 64.01 1,720,376
Jan 26, 2026 62.91 64.39 62.13 63.19 63.19 1,133,081
Jan 23, 2026 64.21 65.11 62.98 63.41 63.41 1,494,188
Jan 22, 2026 62.62 65.38 62.25 64.93 64.93 1,506,323
Jan 21, 2026 64.69 64.77 62.71 63.04 63.04 1,951,498
Jan 20, 2026 61.89 63.81 61.10 63.78 63.78 1,454,037
Jan 16, 2026 63.87 65.35 62.17 62.58 62.58 1,234,063
Jan 15, 2026 64.42 64.98 63.31 63.44 63.44 1,409,671
Jan 14, 2026 63.33 65.08 62.17 64.60 64.60 1,609,680
Jan 13, 2026 64.38 64.38 61.81 63.33 63.33 1,714,627
Jan 12, 2026 62.36 65.25 60.30 64.64 64.64 2,536,392
Jan 9, 2026 64.10 64.98 62.28 62.51 62.51 2,482,911
Jan 8, 2026 65.35 65.90 62.05 63.32 63.32 1,497,431
Jan 7, 2026 65.46 66.59 64.46 65.42 65.42 2,458,709
Jan 6, 2026 61.09 64.89 61.02 64.60 64.60 2,440,625
Jan 5, 2026 61.10 61.66 58.85 61.26 61.26 2,344,929
Jan 2, 2026 63.16 63.96 60.84 61.73 61.73 1,879,705
Dec 31, 2025 61.12 64.43 60.93 63.54 63.54 1,980,880
Dec 30, 2025 61.78 62.40 60.42 61.37 61.37 1,663,553
Dec 29, 2025 62.44 62.72 61.59 61.75 61.75 1,702,113
Dec 26, 2025 64.14 64.17 62.72 63.11 63.11 1,385,385
Dec 24, 2025 63.39 65.28 63.20 64.18 64.18 1,147,704
Dec 23, 2025 64.97 65.27 62.00 63.29 63.29 2,911,776
Dec 22, 2025 64.00 70.98 63.18 65.60 65.60 7,671,878
Dec 19, 2025 62.93 63.70 62.10 62.72 62.72 1,313,652
Dec 18, 2025 62.66 63.80 61.22 62.20 62.20 2,946,739
Dec 17, 2025 62.10 62.26 59.37 59.82 59.82 2,017,333
Dec 16, 2025 61.98 62.36 60.43 62.02 62.02 1,525,633
Dec 15, 2025 63.45 64.12 62.00 62.16 62.16 1,853,186
Dec 12, 2025 60.99 63.80 60.45 63.35 63.35 1,584,176
Dec 11, 2025 60.41 60.99 59.56 60.77 60.77 1,750,175
Dec 10, 2025 61.56 62.27 59.71 60.31 60.31 2,240,035
Dec 9, 2025 64.41 65.45 61.31 61.60 61.60 1,710,811
Dec 8, 2025 65.88 66.37 63.63 64.13 64.13 1,497,529
Dec 5, 2025 66.49 66.95 65.36 65.67 65.67 1,395,064
Dec 4, 2025 64.06 67.26 63.50 66.54 66.54 1,520,048
Dec 3, 2025 63.69 65.51 63.59 64.66 64.66 2,222,756
Dec 2, 2025 65.85 65.85 62.58 63.51 63.51 2,145,301
Dec 1, 2025 67.89 67.99 65.92 66.05 66.05 1,396,653
Nov 28, 2025 68.60 69.33 67.71 68.13 68.13 525,375
Nov 26, 2025 67.95 68.91 67.50 68.15 68.15 1,948,204
Nov 25, 2025 66.86 67.72 66.00 67.55 67.55 2,112,949
Nov 24, 2025 65.50 67.55 64.80 67.21 67.21 1,823,439
Nov 21, 2025 63.46 66.76 63.02 65.44 65.44 1,410,871
Nov 20, 2025 65.38 65.66 62.86 63.50 63.50 1,853,164
Nov 19, 2025 65.39 65.91 63.70 64.79 64.79 2,440,560
Nov 18, 2025 66.45 67.80 66.00 66.16 66.16 1,294,641
Nov 17, 2025 66.01 67.98 65.33 66.95 66.95 2,392,575
Nov 14, 2025 64.11 67.07 64.11 66.44 66.44 2,150,645
Nov 13, 2025 65.28 65.92 64.31 65.52 65.52 2,313,719
Nov 12, 2025 66.51 66.98 65.07 65.94 65.94 2,469,115
Nov 11, 2025 62.16 66.72 61.66 66.50 66.50 2,417,610
Nov 10, 2025 60.30 62.84 60.01 62.20 62.20 1,795,777
Nov 7, 2025 60.20 60.36 58.25 60.16 60.16 1,881,446
Nov 6, 2025 58.85 61.29 58.05 60.30 60.30 2,204,671
Nov 5, 2025 59.34 60.43 58.61 59.19 59.19 1,320,766
Nov 4, 2025 59.55 60.77 58.95 59.62 59.62 979,127
Nov 3, 2025 63.49 63.96 59.11 60.03 60.03 2,142,724
Oct 31, 2025 63.14 63.99 61.69 63.59 63.59 2,430,186
Oct 30, 2025 61.54 64.13 61.49 62.25 62.25 1,542,139
Oct 29, 2025 62.01 63.22 61.01 61.99 61.99 1,912,259
Oct 28, 2025 59.88 62.15 59.52 61.97 61.97 1,939,490
Oct 27, 2025 58.10 60.78 57.83 60.18 60.18 1,461,861
Oct 24, 2025 57.99 58.36 56.98 57.83 57.83 1,067,055
Oct 23, 2025 55.49 58.05 54.30 57.50 57.50 1,890,974
Oct 22, 2025 57.78 57.78 54.45 54.76 54.76 2,659,078
Oct 21, 2025 59.42 59.47 57.66 57.78 57.78 1,081,746
Oct 20, 2025 59.11 60.00 58.44 59.35 59.35 1,381,844
Oct 17, 2025 58.04 59.89 57.51 58.44 58.44 1,162,017
Oct 16, 2025 62.94 63.58 58.40 58.96 58.96 2,138,291
Oct 15, 2025 61.03 63.86 61.00 62.80 62.80 2,043,857
Oct 14, 2025 59.05 61.58 58.84 61.03 61.03 2,173,963
Oct 13, 2025 60.04 61.14 59.46 59.59 59.59 1,379,738
Oct 10, 2025 60.27 60.50 58.58 60.04 60.04 1,313,931
Oct 9, 2025 60.79 61.38 59.43 60.31 60.31 1,320,092
Oct 8, 2025 60.72 61.48 59.64 60.82 60.82 1,663,731
Oct 7, 2025 60.56 61.19 58.74 60.17 60.17 1,784,955
Oct 6, 2025 57.87 61.00 57.27 60.64 60.64 3,020,565
Oct 3, 2025 56.74 58.79 56.20 56.97 56.97 2,457,864
Oct 2, 2025 56.16 56.69 55.33 56.32 56.32 2,004,642
Oct 1, 2025 55.12 56.08 53.61 55.84 55.84 2,066,931
Sep 30, 2025 54.09 55.91 53.57 54.96 54.96 2,811,704
Sep 29, 2025 50.19 54.15 50.15 53.89 53.89 2,944,875
Sep 26, 2025 47.96 50.68 47.87 50.40 50.40 2,096,209
Sep 25, 2025 48.02 48.54 47.22 47.83 47.83 1,625,845
Sep 24, 2025 48.35 49.33 47.73 48.29 48.29 2,087,596
Sep 23, 2025 48.48 50.78 48.40 48.55 48.55 1,904,504

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Cytokinetics Inc. Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at CYTK, per a recent SEC DEF 14A filing. We estimate that the median employee at CYTOKINETICS INC is paid $411,825.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation